Meridian Life Science, Inc @OneMeridianLS

Still relying on cold-chain qPCR workflows? Traditional qPCR mixes depend on refrigerated storage and shipping—raising costs, complicating logistics, and slowing scale-up. As workflows expand, this dependency is becoming harder to sustain. Our NEW Liquid Ambient-Stable DNA qPCR Mixes deliver true ambient stability for 12+ months, maintaining performance in a liquid format with no need for lyophilization or air-drying. Choose the format that fits your development needs: 🔹 MDX360 – Liquid Stable Flex DNA qPCR Mix – Add primers/probes at the point of use for full customization; ideal for low–high throughput and assay optimization. 🔹 MDX364 – Liquid Stable Ready DNA qPCR Mix – A fixed, ready-to-run format with primers/probes added during manufacturing; engineered for scalable, repeatable production. Whether you’re building customizable workflows or fixed high-throughput assays, these mixes reduce cost and complexity—without compromising performance. Explore performance data/compare formats: hubs.la/Q04kB52f0 Contact a specialist/request a sample: hubs.la/Q04kDFHB0 #qPCRmastermixes #MolecularDiagnostics #AssayDevelopment #LifeSciences #PrecisionDiagnostics #NextGenDiagnostics #LiquidStableqPCR #AmbientStability #DiagnosticInnovation #ambientstableassay

Point-of-care diagnostics are transforming how and where testing happens—but challenges around enzyme stability, cost, and logistics can slow adoption. View our on-demand featured presentation "Empowering Molecular Point-of-Care Diagnostics with Ambient-Stable Chemistries" with William Ferreira, R&D Team Leader at Meridian Life Science. Explore how established and emerging molecular techniques—including qPCR, isothermal amplification, and NGS—can be adapted with ambient-stable reagent chemistries to enable faster, more scalable, and cost-effective testing at the point of care. Learn how Meridian’s technologies support: • Molecular point-of-care testing • Ambient-stable, cold-chain-free chemistries • Infectious disease diagnostics • Decentralized and near-patient testing • Rapid assay development in resource-limited settings ▶️ Watch now: hubs.la/Q04ksgrl0 Contact a specialist for more: hubs.la/Q04ks2010 #PointOfCareDiagnostics #MolecularDiagnostics #AmbientStable #ColdChainFree #DecentralizedTesting #InfectiousDisease #AssayDevelopment #LifeScienceInnovation #POCT #EnzymeStability

Meridian’s Lyo-Ready Genotyping Direct qPCR Master Mixes are engineered for ultra-sensitive SNP detection—supporting simplified direct workflows and high-confidence mutation analysis, even at very low copy numbers. Designed for commercial assay developers and molecular diagnostics manufacturers, these mixes deliver reliable performance in both liquid and lyophilized formats. Key advantages: ✅ Ultra-sensitive detection down to 1 copy using direct amplification ✅ High tolerance to common PCR inhibitors ✅ Tight fluorescence clustering for clear allele discrimination ✅ Available in liquid or lyophilized formats for extended shelf life and ambient transport Explore Meridian’s Lyo-Ready Genotyping Direct qPCR Mixes for blood, urine, stool and FFPE. View our product catalog: hubs.la/Q04kgksJ0 Contact a Specialist: hubs.la/Q04kgzNY0 #OncologyDiagnostics #LiquidBiopsy #SNPDetection #qPCR #MolecularDiagnostics #PrecisionOncology #IVD #AssayDevelopers #Lyophilization #genotyping #ambientstable

Get the Pack. Test the Difference. Seeing unexplained variability in your immunoassays? Interference could be the culprit. Try Meridian’s Antibody Interference Blocker Sample Pack and evaluate the impact on assay performance and data reliability—before committing. ☑️ Proven blockers for common immunoassay interferents ☑️ Targets HAMA, RF, and heterophilic antibodies ☑️ Works across ELISA, CLIA, and LFA platforms Choose from serum-based or animal-free options to match your workflow. Explore our blocker portfolio: hubs.la/Q04k7Dtf0 Get your sample pack today: hubs.la/Q04k7FdM0 #immunodiagnostics #antibodyblockers #assaydevelopment #HAMA #rheumatoidfactor #antibodyinterference #CLIA #ELISA #interferenceblockers #immunoassayblockers #HAMA #MouseIgG

Democratizing Access to NGS for Precision Oncology As next-generation sequencing expands beyond centralized labs, access, stability and simplicity are becoming essential to advancing precision oncology worldwide. Meridian is helping to lead this shift with ambient-stable, lyophilized library-preparation reagents designed to remove traditional barriers and enable broader adoption of NGS. What's the Impact? 🔹 Eliminates cold-chain dependence 🔹 Simplifies and streamlines workflows 🔹 Delivers consistent performance 🔹 Supports automation while reducing cost and environmental impact 🔹 Enables fast, reliable, cost-effective sequencing in resource-limited settings By stabilizing key steps across the library prep workflow, we are helping democratize NGS—empowering more labs to bring precision oncology to patients everywhere. Explore the data and download the poster to learn more. hubs.la/Q04jX-PD0 Visit our website: hubs.la/Q04jYglY0 #NGS #PrecisionOncology #Genomics #LifeSciences #MolecularDiagnostics #Biotech #nextgensequencing #LibraryPrep #eliminatecoldchain #pointofcare #ambientstablereagents

Sepsis remains a critical global health challenge where every hour counts. Traditional blood culture methods can be hampered by long turnaround times and inconsistent positivity rates — creating an urgent need for faster, more sensitive molecular approaches. Our clinical case study with PILOT GENE evaluates droplet digital PCR (ddPCR) for bloodstream infection detection, featuring Meridian’s Lyo-Ready qPCR Mix (MDX024) to support robust and reproducible assay performance. Key findings include: • Accelerated diagnostics with significantly reduced time to actionable results • Enhanced pathogen detection in clinical samples • Added insights into antimicrobial resistance • Consistent, reliable performance across formats and sample types when using Lyo-Ready qPCR MIx These results highlight the transformative potential of ddPCR-based workflows in sepsis diagnostics — and Meridian’s commitment to enabling clinical innovation with reliable molecular reagents. Download the full case study to explore the methodology, clinical insights, and implications for advancing sepsis diagnostics. hubs.la/Q04jKhFg0 #SepsisDiagnostics #ddPCR #MolecularDiagnostics #ClinicalInnovation #qPCR #InfectiousDisease #LyophilizedPCR #SepsisDetection #AssayDevelopers

Heading to ESHG 2026 in Gothenburg!? Stop by Booth #462 to discover how ambient-stable molecular solutions can help simplify assay development and support commercialization. From liquid ambient-stable qPCR master mixes to fully lyophilized NGS workflows, Meridian’s technologies are designed to help: ✔ Simplify laboratory workflows ✔ Reduce cold-chain storage and shipping requirements ✔ Support assay stability and reliability ✔ Accelerate the path from development to commercialization Featured at ESHG: 🧬 Liquid ambient-stable DNA qPCR master mixes 🧬 NEW lyophilized NGS enzymatic DNA fragmentation kit 🧬 Fully lyophilized NGS library preparation solutions Whether you’re developing molecular diagnostics, genetic testing assays, or next-generation sequencing workflows, our team is ready to discuss solutions tailored to your development goals. Visit Booth #462 | June 13–16 | Gothenburg, Sweden Schedule a meeting: hubs.la/Q04jyZzq0 Visit our event page: hubs.la/Q04jz2Qt0 #ESHG2026 #HumanGenetics #Genomics #MolecularDiagnostics #NGS #qPCR #AssayDevelopment #GeneticResearch #Diagnostics #LifeScience #nextgensequencing #libraryprep @eshgsociety

As warmer weather returns and mosquito activity increases across many regions, the need for accurate tropical and vector-borne disease testing remains a critical priority. Meridian Life Science helps diagnostic manufacturers develop reliable immunoassays for malaria, dengue, and Zika with high-quality antigens, antibodies, and blockers designed to support assay performance from development through deployment. Our portfolio includes: • Malaria targets including HRP-2, pLDH, aldolase, MSP1, and CSP • Dengue reagents for NS1, IgM, and IgG assay development • Zika solutions, including ZEROX-REACT™ ZIKA Envelope Antigen, engineered to minimize cross-reactivity with other flaviviruses Whether developing laboratory-based or point-of-care assays, our reagents help support sensitive, specific, and reliable test development for global health applications. Learn more: hubs.la/Q04jmMKx0 Contact a specialist: hubs.la/Q04jmM930 #GlobalHealth #AssayDevelopment #ImmunoDiagnostics #DiagnosticDevelopment #TropicalDiseases #VectorBorneDiseases #Malaria #Dengue #Zika #LifeScience #pointofcare #immunoassays

Cold-chain requirements can create real challenges for diagnostic assay developers — from frozen shipments and limited storage space to increased waste and workflow disruption. Meridian’s Liquid Ambient-Stable DNA qPCR Mixes are designed to help reduce that pressure with 12-month ambient stability in a liquid format, without converting assays to a dry state. Choose the format that fits your workflow: MDX360 Liquid Stable Flex DNA qPCR Mix: For teams that need flexibility to add primers and probes at the point of use. MDX364 Liquid Stable Ready DNA qPCR Mix: For developers and manufacturers looking for a more ready-to-run liquid qPCR format. One technology. Two purpose-built formats. More flexibility for development, manufacturing, and point-of-care applications. Explore the data and compare formats: hubs.la/Q04j2FmN0 Contact a Specialist: hubs.la/Q04j2Xcb0 #qPCR #AmbientStable #ReduceColdChain #MolecularDiagnostics #DiagnosticsDevelopment #AssayDevelopment #LifeScience #MolecularReagents #PointOfCareTesting

Is your workflow struggling with clean amplification, balanced coverage, and downstream sequencing accuracy? In a recent customer evaluation, our MDX122 qPCR mix was put to the test in a 177-plex amplicon tNGS assay—and delivered performance equivalent to their commercial kit. Find out how our MDX122 performed across: • Amplification balance • GC-rich targets • Primer-dimer tendency • Uniformity • Downstream accuracy Get the data in our new application note "Inside an Assay Developer’s Study – qPCR for tNGS" hubs.la/Q04j36TT0 Curious how the right qPCR chemistry can strengthen your results?hubs.la/Q04j362p0 #qPCR #targetedNGS #MolecularDiagnostics #AssayDevelopers #PCROptimization #NGSChemistry #ApplicationNote #Genomics #MultiplexPCR #nextgensequencing #tNGS

Are you still battling inconsistent results in your immunoassays? Interference from HAMA, RF, and other heterophilic antibodies can skew data accuracy—especially in post-COVID samples. In this white paper, Meridian introduces TRU Block™, a next-generation universal blocker that delivers stronger, broader protection than traditional agents like Mouse IgG: ✅ Broad coverage against HA, HAMA, and RF ✅ High-affinity binding even at lower concentrations ✅ Proven performance across ELISA, CLIA, and lateral flow assays Enhance assay reliability and reduce costs on retesting Download the white paper: hubs.la/Q04hS-v60 Explore our portfolio of blockers: hubs.la/Q04hSH5T0 Speak to a specialist to request a sample: hubs.la/Q04hT8Dg0 #Immunoassays #AssayDevelopment #TRUBlock #ImmunoDiagnostics #ELISA #LifeScienceDiagnostics #ClinicalLaboratory #HAMA #IVD #LateralFlow #CLIA

For today’s diagnostic assays, animal-free blockers raise the bar even further. They deliver consistently low background, superior lot-to-lot reproducibility, and a defined, ethical alternative to serum-derived materials. That consistency makes them especially well-suited for automated, high-throughput, and globally scaled platforms. Assay interference can quietly undermine immunoassay performance—leading to false positives, unstable signals, and reduced confidence in results. High-quality immunoassay blockers are essential for maintaining assay integrity. They help minimize non-specific binding and reduce interference from HAMA, rheumatoid factor (RF), and heterophilic antibodies—protecting both sensitivity and specificity. Explore our portfolio of high-performance immunoassay blockers: ➡️ Animal-Free HAMA Blockers – Low background, defined composition ➡️ K-BLOCK™ / Mouse-FREE IgG – High-performance, animal-free universal blockers ➡️ TRU Block™ ULTRA, TRU Block™, TRU Block™ 3 – Proven protection against common assay interference ➡️ Mouse IgG – HAMA Blocker – Targeted protection for mouse monoclonal-based assays Consistent blockers. Cleaner data. Greater confidence. Learn more: hubs.la/Q04hFbRp0 Request a sample: hubs.la/Q04hDYKD0 #ImmunoassayBlockers #AssayOptimization #ImmunoDiagnostics #IVDDevelopment #AssayInterference #LifeSciences #Biotech #IgGBlocker #MouseFreeBlocker #MouseFreeReagents

Liquid biopsy is transitioning from a research-driven concept to clinically actionable tools and that shift is starting to have real impact. Advances in next-generation sequencing, molecular detection sensitivity and data analytics are now enabling the identification of genomic alterations that were previously undetectable. This has resulted in earlier insights, more precise stratification and improved monitoring opportunities in oncology workflows. Liquid biopsy is transitioning from a research-driven concept to clinically actionable tools and that shift is starting to have a real impact. academia, diagnostics, pharma and regulatory bodies came together to address critical challenges like validation, reproducibility and standardization. Here’s what’s shaping the future of liquid biopsy: 🔹 The shift from discovery to clinical implementation 🔹 Expansion beyond blood into other biofluids 🔹 The growing role of AI and advanced data analysis 🔹 Increased collaboration across the industry 🔹 Heightened demand for highly sensitive and reproducible assays As the field advances, ensuring consistent, reliable performance will be essential to unlocking the full potential of liquid biopsy in precision oncology. Read the full blog to get more insight: hubs.la/Q04hw6P-0 #LiquidBiopsy #CancerDiagnostics #PrecisionOncology #MolecularDiagnostics #Genomics #NextGenSequencing #BiotechInnovation #AIDiagnostics #LifeSciences #cancerbiomarkers #pointofcare

Meridian is heading to ESHG 2026 in Gothenburg! We’re excited to exhibit at the European Society of Human Genetics (June 13-16) and invite you to visit us at Booth #462 to explore solutions designed to simplify and accelerate molecular assay development and commercialization. At the conference, we’ll be showcasing: 🧬 Liquid ambient-stable DNA qPCR master mixes 🧬 Our newly launched lyophilized NGS enzymatic DNA fragmentation kit 🧬 Fully lyophilized NGS library preparation solutions Our ambient-stable technologies are engineered to help improve assay stability and reliability, maintain high sensitivity, simplify workflows and reduce cold-chain dependency. By supporting faster development timelines and a smoother transition from R&D to commercialization, these innovations help enable broader access to next-generation diagnostics. Schedule a meeting with our team or stop by Booth #462 to learn how Meridian can help streamline workflows, reduce operational complexity and support faster innovation in molecular diagnostics and genetic research. We look forward to seeing you in Gothenburg! Schedule a meeting: hubs.la/Q04h81VJ0 Visit our Event Page: hubs.la/Q04h7Y390 #ESHG2026 #HumanGenetics #Genomics #MolecularDiagnostics #NGS #qPCR #AssayDevelopment #GeneticResearch #Diagnostics #LifeScience #nextgensequencing #libraryprep @eshgsociety

What if qPCR reagents no longer needed to depend on the cold chain? Cold-chain requirements can add cost, complexity, and risk to molecular assay development and distribution. Meridian’s Liquid Ambient-Stable qPCR Mixes help address these challenges with ready-to-use liquid reagents engineered for ambient temperature stability. These liquid-format qPCR mixes are designed to simplify workflows, reduce logistics challenges, and support more scalable molecular testing without compromising performance. Key advantages include: ✅ 12+ months of ambient temperature stability ✅ Reduced reliance on cold-chain shipping and storage ✅ Easier handling with ready-to-use liquid formats ✅ Flexible options for decentralized testing and high-throughput labs ✅ Greater support for sustainable and reliable assay development As molecular diagnostics continue to expand globally, removing cold-chain barriers can help improve accessibility, efficiency, and resilience across the testing landscape. Watch the video to see how Meridian’s Liquid Ambient-Stable qPCR Mixes are helping transform assay development: hubs.ly/Q04h7Sdw0 Learn more | Contact a Specialist hubs.ly/Q04h8hs90 #qPCR #Diagnostics #MolecularDiagnostics #LifeSciences #ColdChainFree #AssayDevelopment #AmbientStableReagents #qPCR #LiquidqPCRmixes

The future of STI testing is being shaped by speed, access, and innovation. As STI rates continue to challenge public health systems worldwide, diagnostic developers are looking for solutions that can support earlier detection, broader access, and more flexible testing models. Meridian’s GEN-sponsored eBook takes a closer look at how molecular diagnostics and immunoassays are helping move STI testing beyond traditional lab settings and into clinics, community programs, point-of-care environments, and at-home collection models. Inside the eBook, explore: 🔹 How STI testing technologies have evolved over time 🔹 Why point-of-care, self-collection, and at-home testing are gaining momentum 🔹 Emerging trends such as multiplexing, ambient-stable reagents, and digital connectivity 🔹 Lessons from four decades of progress in HIV diagnostics As testing becomes more accessible and adaptable, these innovations are helping reduce barriers, support earlier intervention, and improve public health outcomes. Download the free eBook: hubs.la/Q04g-5ZS0 Learn more about our STI Assays: hubs.la/Q04g-Ndx0 #STIDiagnostics #STDtesting #STDprevention #MolecularDiagnostics #Immunoassays #STI #PublicHealth #LifeSciences #PointOfCare #HealthcareInnovation @GENbio

As our Women’s Health Week series comes to a close, we’re highlighting the importance of cervical cancer screening and the role oncoviruses can play in cancer development. Viruses such as HPV, HBV, HCV, EBV and HTLV-1 are associated with cancer progression, and co-infections may further intensify their effects. In cervical cancer, HPV detection remains especially important as screening strategies continue to evolve. According to the American Cancer Society, cervical cancer is most frequently diagnosed in women ages 35 to 64, and cases are rarely seen in women who have received regular screening before age 65. As traditional Pap smears are increasingly complemented or replaced by HPV DNA tests, PCR-based assays offer sensitive detection of multiple HPV types and may support expanded access through patient self-collection-compatible formats. Meridian supports viral oncology research and multiplex assay development with high-performance antigens, antibodies and molecular reagents for sensitive, scalable detection. Meridian’s Lyo-Ready Genotyping Direct qPCR Urine Mix is designed to support fast, precise and reproducible allelic discrimination from urine samples, helping assay developers advance urine-based genotyping workflows. Learn more about viral co-infections and cancer progression: hubs.la/Q04gNMTw0 Explore Meridian’s Lyo-Ready Genotyping Direct qPCR Urine Mix: hubs.la/Q04gNJcN0 #WomensHealthWeek #WomensHealth #EndHPV #CancerPrevention #ViralOncology #LiquidBiopsy #STIdiagostics #DetectOncoviruses #CervicalCancerDetection #NWHW

Women’s Health Week highlights the importance of advancing care for women at every stage of life and how immunoassays continue to play a critical role in women’s health and fertility diagnostics. As testing moves toward more personalized and decentralized care, sensitivity, specificity and reproducibility remain essential for generating clinically meaningful results. From fertility clinics to outpatient and emerging point-of-care settings, assay developers need solutions that support automation, higher throughput and global consistency. Meridian Life Science offers a comprehensive portfolio of immunoassay reagents to support women’s health and fertility testing, including: • high-affinity antibodies and matched pairs for reliable detection of hCG, LH, FSH, estradiol, progesterone, prolactin and TSH • native and recombinant antigens optimized to support assay development • interference mitigation solutions designed to reduce non-specific binding and antibody-mediated interference. Together, these solutions help developers build robust assays across diverse sample types and platforms. Explore our full range of hormone markers and immunoassay solutions. hubs.la/Q04gDtzv0 Contact a Specialist: hubs.la/Q04gBVdl0 #NWHW #WomensHealthWeek #FertilityTesting #Immunoassays #AssayDevelopment #HormoneTesting #Diagnostics #LifeScience #PrecisionDiagnostics #HormoneMarkers #AntibodyInterference

Colorectal cancer remains a major health concern for women and is the second leading cause of cancer death overall in the United States. For adults at average risk, regular screening is recommended beginning at age 45, and detecting colorectal cancer early offers the best chance for successful treatment. While colonoscopy and sigmoidoscopy have long been established screening methods, stool-based tests continue to gain momentum because they are non-invasive and can be completed at home. In particular, multitarget stool DNA testing (FIT-DNA or mt-sDNA) has seen growing adoption since its FDA approval in 2014, helping expand access to convenient screening options by identifying biomarkers associated with colorectal neoplasia. Evidence has shown strong performance of stool DNA testing in screening populations, including adults in the 45 to 49 age group, as screening guidelines continue to emphasize earlier detection. Meridian’s Liquid Biopsy Stool qPCR mixes are designed to support the development of multitarget stool DNA assays, helping assay developers build robust, high-performance workflows for stool-based molecular testing. By enabling innovative non-invasive approaches, these solutions can contribute to better screening strategies and improved outcomes for women and all patients. Learn more: hubs.la/Q04gpvTH0 Request a sample: hubs.la/Q04gpmS-0 #coloncancer #cancerscreening #liquidbiopsy #womenshealthweek #NWHW #precisiononcology #pointofcare #womenspreventativehealth

During Women’s Health Week, it’s important to recognize that breast cancer remains a leading cause of cancer-related death, with approximately 2.3 million new cases diagnosed worldwide each year. The traditional approach to diagnosing breast cancer relies on immunohistochemistry (IHC), a method that is time-consuming and requires skilled pathologists. However, this publication in Biochemistry and Biophysics Reports (hubs.la/Q04gcGJv0) demonstrates the potential to replace IHC with multiplex qPCR analysis using the four standard biomarkers currently used in IHC: estrogen receptor, progesterone receptor, HER2 and Ki-67 proteins. With the millions of breast cancer screening tests performed each year, high-throughput qPCR technology has the potential to improve breast cancer screening and dramatically decrease the turnaround time and cost, while improving the accuracy of cancer detection. Meridian has created high-concentration and glycerol-free enzymes and master mixes to help high-throughput assay developers reduce manufacturing time and produce user-friendly assays. They are designed to minimize sample variation, reduce background noise, facilitate quicker reactions and maintain high-sensitivity levels. Ready to optimize your molecular assays for breast cancer screening? Learn more: hubs.la/Q04gcMC50 Request a sample: hubs.la/Q04gcLd_0 #BreastCancerAwareness #MolecularDiagnostics #CancerScreening #qPCR #ClinicalDiagnostics #LabInnovation #LifeScience #breastcancerdiagnostics #breastcancerscreening #PointofCare #Oncology #NWHW #WomensHealthWeek